Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Alterations in Muscle Tone lll

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Need for Staging System in Colony Stimulating Factor 1 Receptor-Related Disorder.

Movement disorders : official journal of the Movement Disorder Society·2026

Same author

Advances and unmet needs in fluid and tissue biomarkers in Parkinson's disease.

Neural regeneration research·2026

Same author

Charting the translational pathway: ISSCR best practices for the development of PSC-derived therapies.

Stem cell reports·2026

Same author

Investigational Gene Therapies for Parkinson's Disease.

CNS drugs·2025

Same author

Recent advances in fluid and tissue-based biomarkers for use in Parkinson's disease.

Expert review of neurotherapeutics·2025

Same author

Convention vs. innovation III: The promise of stem cell therapy in Parkinson's disease remains bright.

Parkinsonism & related disorders·2025

Search research articles

Related Experiment Video

Updated: May 24, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Disease modification in Parkinson's disease.

Claire Henchcliffe¹, W Lawrence Severt

¹Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, USA. clh2007@med.cornell.edu

|August 5, 2011

Summary

Parkinson's disease treatments face challenges. Recent trials suggest rasagiline may modify disease progression, offering hope beyond symptom management for this neurodegenerative disorder.

Area of Science:

Neuroscience
Pharmacology
Clinical Trials

Background:

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons, leading to motor symptoms like bradykinesia, rigidity, and tremor.
Current treatments focus on dopamine replacement, which alleviates symptoms but does not halt disease progression and has limitations in treating non-motor symptoms.
Developing neuroprotective or disease-modifying therapies is critical for a more fundamental approach to PD, but clinical translation has been challenging due to issues like biomarker validation and preclinical model limitations.

Purpose of the Study:

To review efforts in demonstrating neuroprotection for Parkinson's disease.
To describe ongoing neuroprotection trials in PD.
To critically discuss recent delayed-start clinical trials evaluating the potential disease-modifying effects of rasagiline and pramipexole.

More Related Videos

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Related Experiment Videos

Last Updated: May 24, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Main Methods:

Review of preclinical and clinical studies on neuroprotection in Parkinson's disease.
Analysis of three recent delayed-start design clinical trials.
Focus on trials investigating early versus later initiation of rasagiline and pramipexole.

Main Results:

Two delayed-start trials using rasagiline provided supportive, though not definitive, evidence for disease-modifying effects.
In vitro and animal models suggest neuroprotective properties of rasagiline.
A delayed-start trial of pramipexole reportedly yielded negative results regarding disease-modifying effects.

Conclusions:

Rasagiline shows potential as a disease-modifying agent in Parkinson's disease, supported by clinical trial data and preclinical evidence.
The delayed-start trial design offers a pragmatic approach to assessing disease modification in PD.
Further research is needed to confirm the disease-modifying capabilities of rasagiline and explore other neuroprotective strategies for Parkinson's disease.